FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults
Posted:
The Food and Drug Administration expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
A new “one-stop shop” will be launched so that NHS hospital trusts can access the latest technologies more quickly. Products will be given an “innovator passport”, licensing them for use across the country.
Read more here.
In a study published in Nature Communications, a team of researchers at the University of California, Los Angeles (UCLA) reported an AI tool that virtually stains unlabeled tissue samples at a resolution far exceeding that of the input image—without the use of any…
Attendees
Sponsors and Exhibitors
Contact us